While some studies show that the RB treatment differentiated the SH-SY5Y cells [18, 19, 37], other studies show that the activation of TrkB-BDNF pathway, which is also activated by RB treatment, can lead to increased cell survival, invasion, metastasis, angiogenesis and drug resistance [92–96]. The gene discussed is NTRK2; the disease is retinoblastoma.